Compare CYTK & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | MASI |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.0B |
| IPO Year | 2004 | 2000 |
| Metric | CYTK | MASI |
|---|---|---|
| Price | $70.05 | $175.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 6 |
| Target Price | $85.59 | ★ $184.25 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,368,000.00 | ★ $1,239,153,000.00 |
| Revenue This Year | $341.94 | N/A |
| Revenue Next Year | $48.30 | $6.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.34 |
| 52 Week Low | $29.31 | $125.94 |
| 52 Week High | $70.98 | $194.88 |
| Indicator | CYTK | MASI |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 75.80 |
| Support Level | $59.23 | $137.75 |
| Resistance Level | $67.75 | N/A |
| Average True Range (ATR) | 2.38 | 3.05 |
| MACD | 0.33 | 4.30 |
| Stochastic Oscillator | 79.93 | 99.42 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.